Introduction
============

The pre-participation sports examination (PPE) is a frequent reason for consultation for children and adolescents wishing to engage in sports at the amateur or professional level ([@b1-etm-0-0-8693]). The ultimate goal of PPE is to ensure the safe participation of athletes in sporting activities, most importantly by precluding the existence of conditions predisposing to sudden cardiac death (SCD) during exercise ([@b2-etm-0-0-8693]). Traditionally this involves the taking of a focused patient history and the performance of a physical examination of the cardiovascular and musculoskeletal systems ([@b1-etm-0-0-8693],[@b3-etm-0-0-8693]). More recently, electrocardiogram (ECG) and echocardiographic evaluation have also been gaining ground in the context of PPE ([@b4-etm-0-0-8693],[@b5-etm-0-0-8693]). However, PPE has not been proven to significantly reduce the burden of morbidity/mortality associated with athletic activities ([@b1-etm-0-0-8693]). This may potentially be attributed to the inability of currently employed PPE clinical algorithms and/or diagnostic modalities to adequately detect patients at high risk for SCD ([@b6-etm-0-0-8693]).

Supplementary cardiovascular imaging may offer incremental diagnostic value within existing PPE practices, and this is currently primarily represented by echocardiography. Although echocardiography is a widely available, low-cost imaging modality that does not require the use of ionizing radiation, it is limited by operator- and window-dependency, which can limit reproducibility and diagnostic accuracy, respectively ([@b7-etm-0-0-8693]). Importantly, echocardiography is unable to characterize myocardial tissues with regard to the presence of fibrosis or edema and may even miss structural alterations including apical cardiomyopathy ([@b7-etm-0-0-8693]).

Cardiovascular magnetic resonance (CMR) is the only imaging modality that can compensate for these limitations of echocardiography ([@b10-etm-0-0-8693]). Namely, CMR allows for the identification of arrhythmogenic substrates in patients with normal echocardiographic evaluation ([@b11-etm-0-0-8693]). This is of particular importance in young individuals, as cardiac lesions in this population may initially present directly with ventricular rhythm disturbances (VRDs) and subsequent SCD without prior warning or clinical indications, notably even if echocardiographic evaluation is normal ([@b3-etm-0-0-8693]). Additionally, untreated young patients with ventricular tachycardia (VT) have a worse prognosis ([@b12-etm-0-0-8693]) and thus the identification of clinically silent arrhythmogenic substrates is of paramount importance for the optimization of PPE.

CMR has been studied in adult patients with VRDs and congenital heart disease ([@b13-etm-0-0-8693],[@b14-etm-0-0-8693]) and has been shown to identify children with hypertrophic cardiomyopathy (HCM) at risk of VT ([@b15-etm-0-0-8693]). However, little is known regarding the clinical significance of CMR in the context of PPE. It was hypothesized that in a cohort of young athletes with ECG-demonstrated VRDs and a normal standard PPE and echocardiographic examination, CMR could match the underlying VRDs to arrhythmogenic substrates in the myocardium. Our aim was to evaluate a population of young athletes with VRDs as well as normal echocardiograms and routine PPE using CMR, in order to identify potential arrhythmogenic substrates and to compare their CMR findings with those of a healthy young control athlete population without VRDs.

Patients and methods
====================

### Participants

Prospectively 50 consecutive, asymptomatic, young athletes (henceforth referred to as patients), aged up to 18 years, referred to our tertiary center were recruited (Aghia Sophia Children\'s Hospital, Athens, Greece) from primary care providers of PPE, after identification of VRDs on ECG with otherwise normal standard PPE and echocardiography. They were compared with 20 age- and sex-matched healthy control athletes, who underwent the same evaluations and had no objectifiable abnormalities or symptoms. Healthy control athletes were recruited from a pool of voluntary participants and case-control status was determined a priori based on the presence of any ECG abnormalities, since all study participants were asymptomatic and with normal echocardiograms. CMR findings were not taken into account for the definition of case-control status. VRDs included premature ventricular contractions (PVC) such as bigeminy, trigeminy, couples or triplets and non-sustained VT. Our institution is the national reference center for PPE evaluation, including further evaluation of athletes with abnormal PPE screening. All participants taking part in this study were re-screened at our institution for symptoms related to the cardiovascular system using a standardized structured approach ([@b4-etm-0-0-8693]). This included a detailed individual and family history, clinical evaluation, ECG and echocardiogram, all reviewed by the same physician. The entire cohort was subsequently evaluated using a comprehensive CMR protocol. The study was approved by the medical ethics committee of the Aghia Sophia Children\'s Hospital (protocol no. 27499/29-11-17) and written informed consent was obtained from the parents or legal guardians of the participants.

### CMR evaluation

CMR examinations were performed using a 1.5-T scanner (Ingenia, Philips Medical Systems). The CMR protocol included standard steady-state free-precession cine CMR, black-blood T2-weighted short tau inversion recovery images, T1-weighted spin-echo early gadolinium enhancement (EGE) images, and phase-sensitive inversion recovery late gadolinium enhancement (LGE) images as described previously ([@b16-etm-0-0-8693]). A dose of 0.1 mmol/kg gadobenatedimeglumine contrast-medium was injected for EGE images and another 0.1 mmol/kg for LGE images ([@b16-etm-0-0-8693]).

T1-mapping was performed using a modified Look-Locker inversion recovery (MOLLI) sequence with a 3([@b3-etm-0-0-8693])5 scheme on 3 representative short-axis positions immediately before and 15 min after contrast-medium administration. T2-mapping was performed on 3 representative LV short axis slices using a black-blood prepared, navigator-gated, free-breathing hybrid gradient (echo planar imaging) and spin-echo multiecho sequences ([@b11-etm-0-0-8693]).

### CMR data analysis

Short axis steady-state free-precession cine CMR was used to evaluate biventricular function \[left and right ventricular (LV/RV) end-systolic/-diastolic volumes (ESV/EDV) and ejection fractions (EF)\] following standard practice ([@b17-etm-0-0-8693]). Global myocardial inflammation was assessed using T2-weighted images by calculating the T2 signal intensity ratio of myocardium to skeletal muscle ([@b16-etm-0-0-8693]). Global relative enhancement was calculated by measuring myocardial signal intensity on pre- and post-contrast T1-weighted spin-echo images relative to skeletal muscle ([@b16-etm-0-0-8693]). The presence and pattern of non-ischemic LGE lesions were qualitatively assessed by consensus agreement of 2 experienced observers and expressed as a percentage of LV mass (%LGE). Native and post-contrast T1-mapping, the extracellular volume fraction (ECV) and T2-mapping values were generated using dedicated plugins written for the OsiriX software as described previously ([@b18-etm-0-0-8693]). Global native/post-contrast myocardial T1, ECV, and T2 values were calculated as the mean value of 3 short-axis slices.

### Validation of T1 and T2 measurements

The accuracy of the T1- and T2-mapping methods was evaluated with a relaxometry study using a Eurospin Gel-Phantom (TO5, Diagnostic Sonar LTD, Livingston, Scotland): the comparison of T1 values obtained by the MOLLI 3([@b3-etm-0-0-8693])5 and a reference scan has been previously reported ([@b19-etm-0-0-8693]). T2 values obtained using the black-blood-prepared multiecho hybrid gradient and spin-echo sequence were compared with a spin-echo reference sequence with 16 echoes, 8-msec echo spacing, and 10-sec time to repetition. Furthermore, myocardial T2 values were measured in 16 myocardial segments in an additional control group to assess reproducibility and regional variations of estimated myocardial T2 signals ([@b19-etm-0-0-8693]). This control group consisted of 20 healthy, asymptomatic subjects (median age, 15 years \[IQR, 12-18 years\]) without cardiovascular disease. Inter-scan reproducibility was assessed for myocardial T1 and T2 measurements by performing 10 repeated scans with identical imaging parameters. An inter-observer agreement of 0.85 was observed between 2 blinded observers in all subjects.

### Locally determined cut-off values for CMR variables

Locally determined cut-off points for tissue characterization indices were LGE \>0%, EGE \>4, T2 signal ratio \>1.9, native T1-mapping \>1,050 msec, post-contrast T1-mapping \<350 msec, T2-mapping \>55 msec and ECV \>28%.

### Diagnostic criteria

Where applicable, the diagnosis of acute/chronic infectious/non-infectious myocarditis was based on the 2009 Lake Louise criteria ([@b16-etm-0-0-8693]), that of arrhythmogenic right ventricular cardiomyopathy (ARVC) on the Task Force Criteria for pediatric ARVC ([@b20-etm-0-0-8693]), that of non-compaction cardiomyopathy on published criteria for non-compaction cardiomyopathy in children ([@b21-etm-0-0-8693]) and that of Duchenne/Becker muscular dystrophy (DMD/BMD) patient/carrier status on the presence of subepicardial LGE in the lateral LV wall ([@b22-etm-0-0-8693]).

### Statistical analysis

Statistical analyses were carried out using Stata v.15SE and R v.3.6.0. Normally distributed variables are presented as mean (standard deviation), continuous not-normally distributed variables are presented as median (interquartile range) and binary/categorical variables are presented as number (percentage). The primary outcome was patient vs. control status and the secondary outcome was patients with VT vs. patients without VT. Descriptive statistics were determined and evaluated for statistical significance between each of the groups per outcome using the independent-sample t-test, Mann-Whitney U test and Chi-square test for normally distributed, not-normally distributed continuous and binary/categorical variables, respectively. Similarly, when comparing more than two groups, a one-way analysis of variance, the Kruskal-Wallis test and the chi-square test were used, respectively.

Logistic regression analyses were used to apply multivariable corrections for age and sex to CMR predictors of the primary and secondary outcomes. The ncvreg package ([@b23-etm-0-0-8693]) was used for performing min/max concave penalty (MCP) logistic regression analyses with k-fold cross-validation for both outcomes in order to inform variable selection for multivariable models. Indexed ventricular volumes, ventricular ejection fractions and tissue characterization indices, age and sex were included as potential features to be selected. The optimal value for the penalization term λ was determined as the value that minimizes the cross-validation error rate. The reliability of selected features was evaluated using the built-in marginal false discovery rate (mFDR), which performs better than other inference methods for penalized regression analyses ([@b24-etm-0-0-8693],[@b25-etm-0-0-8693]). Signal-to-noise ratios are also presented. Model predictive capacities are reported as cross-validated R^2^ values. Penalized regression analyses often overcome the disadvantages of stepwise or best subset approaches for feature selection ([@b26-etm-0-0-8693]) and allow for the selection of important predictors by optimizing the variance-bias trade-off ([@b27-etm-0-0-8693]). This in turn increases the external validity of the identified predictors at the cost of more biased estimates. The employed type of penalization (MCP) has been shown to be less biased towards features with larger coefficients than other penalization methods such as least absolute shrinkage and selection operator (LASSO) ([@b23-etm-0-0-8693],[@b26-etm-0-0-8693]) and was thus preferred for statistical analyses presented in this manuscript.

Results
=======

Baseline characteristics of the included patients and control athletes are presented in [Table I](#tI-etm-0-0-8693){ref-type="table"}. The median ages (IQR) of the former and latter were 13.5 (11.0-17.0) and 15 (12.0-18.0) years, respectively (p=0.37). Similarly, the proportion of females was 19 (38%) and 10 (50%), respectively (P=0.36). Regarding the previous medical history of the patient group, 1 (2%) patient had known Hashimoto\'s thyroiditis and was under appropriate endocrinologic treatment. The remainder of the patient cohort (n=49, 98%) had no known past medical history. The totality of the patient cohort had no objectifiable cardiovascular symptoms. For each of the 50 asymptomatic patients with normal echocardiographic evaluation and documented VRDs, a clinical diagnosis was made based on CMR findings in combination with clinical and diagnostic information. Namely, 20 (40%) were diagnosed with recent-onset myocarditis, 8 (16%) with remitting past myocarditis (previous PPE with ECG was normal in these participants), 9 (18%) with ARVC, 5 (10%) with non-compaction cardiomyopathy, 2 (4%) with female-carrier status of DMD, 3 (6%) males with BMD, 1 (2%) with dilated cardiomyopathy, 1 (2%) with Hashimoto thyroiditis with cardiac involvement and 1 (2%) with HCM. The aforementioned diagnoses were not known at the time of CMR evaluation.

Patients had significantly higher indexed diastolic ventricular volumes compared with control athletes and tissue characterization indices differed significantly between groups ([Table I](#tI-etm-0-0-8693){ref-type="table"}). This was especially the case for LGE which was identified in none of the controls, but in 40 (80%) of the patients (P\<0.0001). Native T1-mapping and ECV were similarly abnormal in a large majority of the patients compared with none of the controls \[21 (42%) and 24 (48%), respectively, P\<0.001 for both\]. No statistically significant differences were identified in LV/RVEF between the two groups. In contrast to the comparisons between patients and controls, few significant differences were identified between patients with and without VT ([Table II](#tII-etm-0-0-8693){ref-type="table"}). These were reflected by overall significantly smaller indexed biventricular volumes in the VT group without significant differences in LV/RVEF or tissue characterization indices. There was a trend for a smaller proportion of abnormal EGE values in the VT group compared with the non-VT group, but this did not reach statistical significance \[1 (5%) vs. 7 (24%), P=0.065\]. The predominant cardiac condition in the non-VT group was recent-onset myocarditis \[17 (59%)\] while that of the VT group was ARVC \[9 (43%)\] (P=0.001).

Results of univariable and multivariable logistic regression analyses are presented for both the primary and secondary outcomes in [Table III](#tIII-etm-0-0-8693){ref-type="table"}. When adjusted for age and sex, indexed LVEDV and RVEF were significant positive predictors of the primary outcome. There was a trend for indexed RVEDV as an independent predictor, but this did not reach statistical significance \[odds ratio (OR) 1.07 (95% CI 1.00-1.16), P=0.066\]. Most tissue characterization indices independently predicted the primary outcome with increasing values, with LGE and EGE having the greatest contribution. The presence of LGE namely predicted the primary outcome perfectly and EGE had an OR of 6.35 (95% CI 2.19-21.62) per 0.5-unit change for the primary outcome in multivariable analysis (P\<0.001). At ≥1.3 cut-off, EGE had a sensitivity and specificity of 88 and 85%, respectively for predicting the primary outcome with 87.1% accuracy (area under the receiver operator characteristics curve: 0.935). Conversely, only indexed LV/RV EDV/ESV were negative independent predictors of the secondary endpoint. EGE and native T1-mapping trended towards significance as independent predictors of the secondary outcome but did not reach statistical significance \[OR (95% CI): 0.82 (0.65-1.03), P=0.090 and 1.10 (0.99-1.21), P=0.073, respectively\].

A penalized logistic regression analysis employing the MCP penalization method was used for feature selection as described in the methods section. The results for both the primary and secondary outcomes are presented in [Tables IV](#tIV-etm-0-0-8693){ref-type="table"} and [V](#tV-etm-0-0-8693){ref-type="table"}, respectively. For the primary outcome, LGE, EGE, ECV and T2-mapping were selected. For the secondary outcome, indexed RVEDV and native T1-mapping were the selected features. Feature reliability can be evaluated using the mFDR of each selected feature. Based on this, for the primary end point the first three features are the least likely to be false discoveries ([Table IV](#tIV-etm-0-0-8693){ref-type="table"}). For the secondary endpoint, indexed RVEDV is least likely to be a false discovery although with a relatively high mFDR. As a sensitivity analysis, the MCP penalized regression was re-run for the primary outcome using only the subset with VT vs. controls and no-VT vs. controls separately. However, the results were almost identical to the pooled analysis for the primary outcome. An additional sensitivity analysis was run to compare different types of cardiomyopathies (with at least n ≥5 patients) with regard to baseline characteristics using standard univariable statistics ([Table VI](#tVI-etm-0-0-8693){ref-type="table"}). Only the proportion of patients with pathologic T2-mapping values was significantly different between groups. Namely it was present only in patients with myocarditis and DMD/BMD \[9 (45%) and 1 (20%), respectively\] and absent in all other types of cardiomyopathies (P=0.013).

Discussion
==========

In a cohort of 50 asymptomatic young athletes presenting for PPE and referred for additional evaluation due to documented VRDs with otherwise normal standard examination with echocardiographic evaluation, CMR identified arrhythmogenic substrates in all participants. In athletes with VRDs other than VT the predominant cardiac condition was recent-onset myocarditis, while the majority of those with VT were diagnosed with ARVC. Tissue characterization indices discriminated between cases and a cohort of 20 healthy control athletes independent of age and sex, as did indexed LVEDV and RVEF. Based on penalized regression analysis, the most valuable indices for discriminating between case-control status were LGE, EGE, ECV and T2-mapping in that order. Only indexed ventricular volumes independently discriminated between athletes with VRD with and without VT. Penalized regression analysis identified indexed RVEDV and native T1-mapping as the most useful indices for VT vs. no-VT discrimination, albeit with a high error margin.

Our findings suggest a multifaceted contribution of CMR in PPE. Next to its ability to assess tissue changes in the myocardium, CMR also led to the establishment of a new diagnosis in all athletes in this cohort. This is in agreement with previous studies performed by our group and others albeit in adult populations ([@b28-etm-0-0-8693],[@b29-etm-0-0-8693]). Interestingly, although ventricular function did not differ significantly between athletes with VRD and healthy controls, this was not the case for CMR-derived tissue characterization indices, of which, LGE, EGE and ECV had the best discriminatory value. CMR findings in conjunction with clinical assessment allowed the diagnosis of acute and/or chronic cardiac pathology that clarified the observed arrhythmogenicity despite normal echocardiographic findings.

The diagnostic contribution of CMR in the workup of patients with suspected myocarditis/cardiomyopathies is generally well represented in the literature. ARVC in particular may be detected in endurance athletes with VRDs and a normal RV structure, as well as function-wise ([@b30-etm-0-0-8693]). Additionally, 50% of patients with non-compaction cardiomyopathy may not be identified using echocardiographic evaluation alone, instead requiring disease demonstration with CMR ([@b31-etm-0-0-8693],[@b32-etm-0-0-8693]). In children with HCM, myocardial fibrosis identified using LGE was associated with adverse events ([@b15-etm-0-0-8693]) and diffuse ventricular fibrosis identified by T1-mapping predicted non-sustained VT and aborted SCD in adult HCM patients ([@b33-etm-0-0-8693]). CMR has recently been shown to aid in the workup of patients with seemingly idiopathic VRDs, which by extension can facilitate further diagnostic and therapeutic decision making ([@b34-etm-0-0-8693]). Furthermore, a normal CMR examination corresponded to a low annual risk of adverse events in a large cohort of patients with suspected myocarditis ([@b29-etm-0-0-8693]). In patients with thyroid disease CMR identified myocardial inflammation using T2 signal ratio ([@b28-etm-0-0-8693]). Lastly, in both patients and carriers of DMD, CMR can uniquely reveal myocardial fibrosis as areas of LGE ([@b35-etm-0-0-8693],[@b36-etm-0-0-8693]) or pathologically elevated T1-mapping ([@b37-etm-0-0-8693]) functioning as arrhythmogenic loci. The more novel CMR indices, namely T1-mapping, T2-mapping and ECV, have also recently been incorporated in the routine CMR evaluation of patients with (suspected) myocarditis or cardiomyopathies ([@b38-etm-0-0-8693]), signifying their transition from research tools to indices capable of guiding clinical practice.

To our knowledge, this is the only study in the literature presenting a CMR-PPE assessment of young athletes presenting with VRDs and normal echocardiographic evaluation. Our study demonstrates that suspicious ECG findings not corroborated by echocardiography should motivate further assessment using CMR in the context of PPE. In these cases, CMR not only allowed for the establishment of clinical diagnoses with confidence, but also prompted limitation of physical exercise and appropriate diagnostic and therapeutic follow-up according to current practice guidelines. Our findings thus suggest that in cases where echocardiography cannot guide clinical decision making due to equivocal results, CMR can provide an additive, diagnostic value. An additional innovation of this study was the inclusion of penalized regression analyses that allowed the optimal selection of features such that external validity is optimized. To our knowledge this method has not been employed in previous CMR studies except for a single study by our group ([@b39-etm-0-0-8693]) and a single methodological study using brain MR, which yielded highly accurate feature selection ([@b26-etm-0-0-8693]).

PPE in adolescents is considered to have an unfavorable cost-benefit trade-off, with one study even suggesting that adding ECG evaluation to PPE at a cost of \$50.000/quality adjusted life year is not cost-effective mainly due to false-positive findings ([@b40-etm-0-0-8693]). Our study provides for the first time evidence against this claim, as the authors do not mention whether CMR was used in cases of pathologic ECG findings, instead grouping all interventions into a collective 'referral to cardiology'. The study did demonstrate that the addition of ECG led to identification of additional SCD patients, despite not being cost-effective. Our findings, however, suggest that false positive findings might in fact be falsely ruled-out and could be reclassified after further investigation with CMR. Although we did not systematically investigate cost-effectiveness and it is clearly impractical to recommend a CMR examination for all athletes with pathologic ECG findings, our study raises doubts regarding the currently perceived notions around the cost-effectiveness of PPE, which should be reiterated in future studies after the inclusion of CMR.

Our study has some limitations. Only athletes with VRDs were referred to our tertiary center for CMR evaluation, thus introducing a potential selection bias. The predictive capacity of CMR-PPE could not be evaluated due to lack of sufficient clinical follow-up. Additionally, we did not evaluate a uniform population but rather an ensemble of different cardiac pathologies, which may have skewed our results depending on which condition was most prevalent. However, only the proportion of patients with pathologic T2-mapping values differed significantly between the most prevalent types of cardiac pathology. This might have additionally influenced the analysis of the secondary outcome for the same reason, as the VT and non-VT groups had a different prevalence of cardiac pathologies.

To conclude, in this case-control study it was demonstrated for the first time that young athletes presenting with a request for PPE and having VRDs and normal echocardiograms can be optimally discriminated from healthy control athletes using the CMR-derived indices LGE, EGE, ECV and T2-mapping. Furthermore, CMR provided valuable diagnostic utility by allowing for the identification of arrhythmogenic substrates in all cases. This brings current notions regarding the cost-effectiveness of ECG and CMR in PPE into doubt. However, further multicenter studies are needed to assess the cost-effectiveness of this approach, to establish a selection algorithm for CMR-PPE and to evaluate the potential improvements in long-term clinical outcome with the addition of CMR in PPE.
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###### 

Comparison of baseline characteristics between control athletes and asymptomatic athletes with VRD.

  Variable                                                         Control athletes       Patients                   P-value
  ---------------------------------------------------------------- ---------------------- -------------------------- -------------------------------------------------------
  Demographics                                                                                                       
       Participant no.                                             20                     50                         N/A
       Female sex                                                  10 (50%)               19 (38%)                   0.36
       Age (years)                                                 15.0 (12.0, 18.0)      13.5 (11.0, 17.0)          0.37
  Type of cardiac pathology                                                                                          
       Recent-onset myocarditis                                    N/A                    20 (40%)                   N/A
       ARVC                                                                               9 (18%)                    
       Past myocarditis                                                                   8 (16%)                    
       DMD/BMD                                                                            5 (10%)                    
       Non-compaction cardiomyopathy                                                      5 (10%)                    
       DCM                                                                                1 (2%)                     
       Hashimoto thyroiditis                                                              1 (2%)                     
       LV hypertrophy                                                                     1 (2%)                     
  Types of rhythm disturbances                                                                                       
       PVCs in couples                                             N/A                    7 (14%)                    N/A
       PVCs in triplets                                                                   9 (18%)                    
       Bigeminy                                                                           9 (18%)                    
       Trigeminy                                                                          4 (8%)                     
       VT                                                                                 21 (42%)                   
  Ventricular volumes and function                                                                                   
       LVEDV (ml)                                                  103.5 (96.5, 105.0)    127.0 (104.0, 155.0)       0.002^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       LVESV (ml)                                                  39.0 (31.5, 41.0)      46.0 (36.0, 56.0)          0.013^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       LVEF (%)                                                    63.0 (62.0, 68.0)      63.0 (59.0, 67.0)          0.21
       RVEDV (ml)                                                  100.0 (92.5, 113.5)    126.0 (97.0, 144.0)        0.011^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       RVESV (ml)                                                  41.5 (33.0, 49.0)      49.0 (34.0, 63.0)          0.17
       RVEF (%)                                                    59.5 (54.0, 63.5)      62.0 (59.0, 64.0)          0.12
  Indexed ventricular volumes                                                                                        
       LVEDV/BSA                                                   67.4 (59.4, 72.4)      72.9 (67.1, 86.1)          0.018^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       LVESV/BSA                                                   22.8 (20.3, 28.4)      26.1 (22.7, 34.3)          0.067
       RVEDV/BSA                                                   63.2 (52.9, 72.6)      73.4 (61.3, 88.0)          0.043^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       RVESV/BSA                                                   25.4 (22.2, 30.9)      28.5 (21.1, 36.2)          0.45
  Tissue characterization indices                                                                                    
       EGE                                                         0.6 (0.2, 1.0)         2.6 (1.5, 3.8)             \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       LGE (%)                                                     0.0 (0.0, 0.0)         5.0 (2.0, 5.0)             \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       T2 signal ratio                                             1.4 (1.2, 2.0)         2.0 (1.8, 2.4)             \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       Native T1-mapping (msec)                                    955.5 (944.0, 980.0)   1,045.5 (997.0, 1,098.0)   \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       Post-contrast T1-mapping (msec)                             467.0 (455.0, 478.5)   445.0 (414.0, 481.0)       0.064
       ECV (%)                                                     25.5 (24.5, 27.0)      28.0 (26.0, 31.0)          \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       T2-mapping (msec)                                           47.0 (43.0, 49.5)      50.0 (48.0, 53.0)          \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
  Locally-used normal values for tissue characterization indices                                                     
       EGE \>4                                                     0 (0%)                 8 (16%)                    0.057
       LGE \>0%                                                    0 (0%)                 40 (80%)                   \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       T2 signal ratio \>1.9                                       6 (30%)                30 (60%)                   0.023^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       Native T1-mapping \>1,050 msec                              0 (0%)                 21 (42%)                   \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       Post-contrast T1-mapping \<350 msec                         0 (0%)                 4 (8%)                     0.19
       T2-mapping \>55 msec                                        0 (0%)                 10 (20%)                   0.031^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^
       ECV \>28%                                                   0 (0%)                 24 (48%)                   \<0.001^[a](#tfn1-etm-0-0-8693){ref-type="table-fn"}^

^a^P≤0.05. VRD, ventricular rhythm disturbance; ARVC, arrhythmogenic right ventricular cardiomyopathy; DMD/BMD, Duchenne/Becker muscular dystrophy; DCM, dilated cardiomyopathy; PVC, premature ventricular contraction; VT, non-sustained ventricular tachycardia; LV/RV, left/right ventricular; EDV/ESV, end-diastolic/-systolic volume; EF, ejection fraction; BSA, body surface area; EGE/LGE, early/late gadolinium enhancement; ECV, extracellular volume fraction.

###### 

Comparison of baseline characteristics between VRD patients that did and did not experience VT.

  Variables                                                        No VT                      VT                           P-value
  ---------------------------------------------------------------- -------------------------- ---------------------------- -----------------------------------------------------
  Demographics                                                                                                             
       Participant no.                                             29                         21                           N/A
       Female sex                                                  13 (45%)                   6 (29%)                      0.24
       Age (years)                                                 14.0 (12.0, 17.0)          15.0 (13.0, 18.0)            0.35
  Type of cardiac pathology                                                                                                
       Recent-onset myocarditis                                    17 (59%)                   3 (14%)                      0.001^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
       ARVC                                                        0 (0%)                     9 (43%)                      
       Past myocarditis                                            5 (17%)                    3 (14%)                      
       DMD/BMD                                                     2 (7%)                     3 (14%)                      
       Non-compaction cardiomyopathy                               4 (14%)                    1 (5%)                       
       DCM                                                         0 (0%)                     1 (5%)                       
       Hashimoto thyroiditis                                       0 (0%)                     1 (5%)                       
       LV hypertrophy                                              1 (3%)                     0 (0%)                       
  Ventricular volumes and function                                                                                         
       LVEDV (ml)                                                  132.0 (117.0, 154.0)       110.0 (90.0, 160.0)          0.16
       LVESV (ml)                                                  52.0 (41.0, 57.0)          37.0 (32.0, 52.0)            0.10
       LVEF (%)                                                    63.0 (59.0, 66.0)          63.0 (59.0, 67.0)            0.86
       RVEDV (ml)                                                  134.0 (106.0, 156.0)       115.0 (78.0, 127.0)          0.035^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
       RVESV (ml)                                                  51.0 (43.0, 68.0)          43.0 (29.0, 54.0)            0.072
       RVEF (%)                                                    62.0 (60.0, 63.0)          62.0 (56.0, 64.0)            0.92
  Indexed ventricular volumes                                                                                              
       LVEDV/BSA                                                   76.8 (71.8, 86.1)          68.9 (54.0, 77.8)            0.031^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
       LVESV/BSA                                                   29.9 (24.9, 36.2)          23.5 (21.3, 27.6)            0.028^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
       RVEDV/BSA                                                   81.2 (69.2, 92.3)          69.3 (49.6, 76.1)            0.019^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
       RVESV/BSA                                                   32.8 (27.3, 36.6)          25.5 (19.4, 33.5)            0.019^[a](#tfn2-etm-0-0-8693){ref-type="table-fn"}^
  Tissue characterization indices                                                                                          
       EGE                                                         3.0 (1.6, 4.0)             2.5 (1.5, 3.5)               0.21
       LGE (%)                                                     5.0 (4.0, 5.0)             5.0 (2.0, 5.0)               0.32
       T2 signal ratio                                             2.0 (1.9, 2.4)             2.0 (1.7, 2.4)               0.49
       Native T1-mapping (msec)                                    1,042.0 (990.0, 1,092.0)   1,051.0 (1,011.0, 1,125.0)   0.30
       Post-contrast T1-mapping (msec)                             445.0 (416.0, 492.0)       445.0 (414.0, 455.0)         0.40
       ECV (%)                                                     28.0 (26.0, 31.0)          28.0 (26.0, 31.0)            0.81
       T2-mapping (msec)                                           50.0 (48.0, 53.0)          50.0 (48.0, 52.0)            0.55
  Locally-used normal values for tissue characterization indices                                                           
       EGE \>4                                                     7 (24%)                    1 (5%)                       0.065
       LGE \>0%                                                    24 (83%)                   16 (76%)                     0.57
       T2 signal ratio \>1.9                                       18 (62%)                   12 (57%)                     0.73
       Native T1-mapping \>1,050 msec                              10 (34%)                   11 (52%)                     0.21
       Post-contrast T1-mapping \<350 msec                         2 (7%)                     2 (10%)                      0.74
       T2-mapping \>55 msec                                        7 (24%)                    3 (14%)                      0.39
       ECV \>28%                                                   14 (48%)                   10 (48%)                     0.96

^a^P≤0.05. VT, non-sustained ventricular tachycardia; ARVC, arrhythmogenic right ventricular cardiomyopathy; DMD/BMD, Duchenne/Becker muscular dystrophy; DCM, dilated cardiomyopathy; LV/RV, left/right ventricular; EDV/ESV, end-diastolic/-systolic volume; EF, ejection fraction; BSA, body surface area; EGE/LGE, early/late gadolinium enhancement; ECV, extracellular volume fraction.

###### 

Results of univariable and multivariable logistic regression analysis for discriminating between patients with VRDs and healthy controls (positive outcome: patient) and amongst VRD patients with and without VT (positive outcome: VT).^[a](#tfn3-etm-0-0-8693){ref-type="table-fn"}^

                                                Patients vs. controls   VT vs. no VT patients                                                                                                                                                                                                            
  --------------------------------------------- ----------------------- ------------------------------------------------------- -------------------- ------------------------------------------------------- ------------------ ----------------------------------------------------- ------------------ -----------------------------------------------------
  Ventricular volumes and function                                                                                                                                                                                                                                                                       
       LVEDV/BSA                                1.04 (1.00-1.08)        0.031^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     1.05 (1.00-1.09)     0.028^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     0.97 (0.94-1.00)   0.072                                                 0.96 (0.92-0.99)   0.026^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^
       LVESV/BSA                                1.07 (0.99-1.14)        0.073                                                   1.07 (1.00-1.16)     0.066                                                   0.94 (0.88-1.01)   0.092                                                 0.92 (0.86-1.00)   0.037^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^
       LVEF (per 5%)                            0.93 (0.84-1.03)        0.146                                                   0.67 (0.39-1.14)     0.137                                                   1.01 (0.91-1.12)   0.874                                                 1.13 (0.66-1.92)   0.660
       RVEDV/BSA                                1.03 (0.99-1.06)        0.071                                                   1.03 (1.00-1.06)     0.065                                                   0.97 (0.94-0.99)   0.029^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   0.96 (0.93-0.99)   0.011^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^
       RVESV/BSA                                1.02 (0.97-1.07)        0.517                                                   1.02 (0.96-1.07)     0.527                                                   0.94 (0.88-1.00)   0.054                                                 0.93 (0.87-0.99)   0.026^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^
       RVEF (per 5%)                            1.09 (1.01-1.17)        0.038^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     1.10 (1.01-1.20)     0.023^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     0.98 (0.89-1.08)   0.725                                                 0.96 (0.59-1.57)   0.876
  Tissue characterization indices:                                                                                                                                                                                                                                                                       
       T2 signal ratio (per 0.1 unit-change)    1.41 (1.18-1.69)        \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   1.41 (1.18-1.70)     \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   0.95 (0.84-1.09)   0.482                                                 0.91 (0.78-1.05)   0.205
       EGE (per 0.5 unit-change)                3.98 (1.92-8.26)        \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   6.89 (2.19-21.62)    \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   0.85 (0.69-1.05)   0.126                                                 0.82 (0.65-1.03)   0.090
       LGE (%)                                  Perfect prediction                                                              Perfect prediction                                                           0.90 (0.71-1.14)   0.400                                                 0.87 (0.67-1.12)   0.283
       Native T1-mapping (per 10 msec)          1.43 (1.17-1.75)        \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   1.49 (1.20-1.84)     \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   1.06 (0.99-1.13)   0.089                                                 1.10 (0.99-1.21)   0.073
       Post-contrast T1-mapping (per 10 msec)   0.90 (0.80-1.02)        0.099                                                   0.91 (0.80-1.02)     0.115                                                   0.95 (0.87-1.04)   0.248                                                 0.95 (0.87-1.04)   0.266
       ECV (%)                                  1.58 (1.20-2.07)        0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     1.66 (1.25-2.22)     \<0.001^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^   1.02 (0.87-1.20)   0.776                                                 1.06 (0.89-1.26)   0.496
       T2-mapping (msec)                        1.36 (1.12-1.65)        0.002^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     1.40 (1.13-1.72)     0.002^[b](#tfn4-etm-0-0-8693){ref-type="table-fn"}^     0.95 (0.85-1.07)   0.418                                                 0.93 (0.82-1.06)   0.286

^a^Multivariable corrections were for age and sex. Ventricular volumes were previously indexed by dividing each parameter with the body surface area of the participants (denoted as '/BSA').

^b^P≤0.05. VRD, ventricular rhythm disturbance; VT, non-sustained ventricular tachycardia; BSA, body surface area; LV/RV, left/right ventricular; EDV/ESV, end-diastolic/-systolic volume; EF, ejection fraction; EGE/LGE, early/late gadolinium enhancement; ECV, extracellular volume fraction.

###### 

Results of MCP-logistic regression analysis for differentiating VRD patients from healthy controls.

  Variables                   Estimate   z-value   Average mFDR   Cross-validated mFDR   R^2^   Signal-to-noise ratio   Prediction error
  --------------------------- ---------- --------- -------------- ---------------------- ------ ----------------------- ------------------
  LGE (%)                     5.946      24.34     0.0001         0.266                  0.63   1.68                    0.029
  EGE (per 0.5 unit-change)   0.832      3.433     0.0012                                                               
  ECV (%)                     0.595      2.987     0.0501                                                               
  T2-mapping (msec)           0.082      1.414     1.0000                                                               

MCP, minmax concave penalty; VRD, ventricular rhythm disturbance; mFDR, marginal false discovery rate; EGE/LGE, early/late gadolinium enhancement; ECV, extracellular volume fraction.

###### 

Results of MCP-logistic regression analysis for differentiating VRD patients with VT from those without VT.

  Variables                         Estimate   z-value   Average mFDR   Cross-validated mFDR   R^2^      Signal-to-noise ratio   Prediction error
  --------------------------------- ---------- --------- -------------- ---------------------- --------- ----------------------- ------------------
  RVEDV/BSA                         -0.0105    -2.351    0.327          0.578                  \<0.001   \<0.001                 0.48
  Native T1-mapping (per 10 msec)   0.0005     1.761     0.830                                                                   

MCP, minmax concave penalty; VT, non-sustained ventricular tachycardia; mFDR, marginal false discovery rate; RVEDV, right ventricular end-diastolic volume; BSA, body surface area.

###### 

Comparison of different types of cardiomyopathies with regard to baseline characteristics.

  Variables                                                        Myocarditis                Past myocarditis             ARVC                       DMD/BMD                      Non-compaction cardiomyopathy   P-value
  ---------------------------------------------------------------- -------------------------- ---------------------------- -------------------------- ---------------------------- ------------------------------- -----------------------------------------------------
  Demographics                                                                                                                                                                                                     
       Participant no.                                             20                         8                            9                          5                            5                               N/A
       Female sex                                                  11 (55%)                   3 (38%)                      1 (11%)                    2 (40%)                      2 (40%)                         0.29
       Age (years)                                                 15.0 (13.5, 18.0)          14.5 (10.0, 19.0)            16.0 (14.0, 17.0)          14.0 (12.0, 15.0)            11.0 (10.0, 13.0)               0.38
  Ventricular volumes and function                                                                                                                                                                                 
       LVEDV (ml)                                                  133.0 (117.5, 156.0)       124.5 (103.5, 165.0)         140.0 (95.0, 160.0)        89.0 (86.0, 125.0)           117.0 (109.0, 126.0)            0.73
       LVESV (ml)                                                  52.0 (39.0, 55.5)          49.5 (36.5, 70.0)            43.0 (36.0, 52.0)          39.0 (32.0, 46.0)            42.0 (35.0, 51.0)               0.66
       LVEF (%)                                                    63.0 (60.0, 66.0)          61.0 (55.0, 62.5)            66.0 (62.0, 67.0)          60.0 (59.0, 63.0)            66.0 (57.0, 68.0)               0.42
       RVEDV (ml)                                                  142.0 (119.0, 166.5)       122.5 (110.5, 148.0)         122.0 (97.0, 127.0)        98.0 (95.0, 104.0)           96.0 (91.0, 134.0)              0.16
       RVESV (ml)                                                  58.5 (41.5, 71.5)          46.5 (41.5, 52.0)            44.0 (34.0, 53.0)          34.0 (33.0, 37.0)            43.0 (33.0, 51.0)               0.25
       RVEF (%)                                                    62.0 (60.0, 63.0)          60.5 (56.5, 62.5)            64.0 (56.0, 66.0)          64.0 (63.0, 65.0)            63.0 (61.0, 63.0)               0.44
  Indexed ventricular volumes                                                                                                                                                                                      
       LVEDV/BSA                                                   72.8 (65.3, 86.1)          79.0 (67.7, 89.7)            70.4 (68.3, 77.8)          72.3 (53.2, 80.0)            74.6 (72.4, 80.8)               0.88
       LVESV/BSA                                                   26.3 (23.1, 35.7)          30.6 (25.3, 36.9)            22.9 (22.0, 26.0)          29.4 (21.3, 31.7)            24.9 (22.3, 35.2)               0.53
       RVEDV/BSA                                                   74.6 (69.2, 99.3)          82.5 (62.5, 88.9)            69.8 (59.5, 72.7)          62.7 (58.5, 77.1)            66.3 (53.9, 82.0)               0.39
       RVESV/BSA                                                   31.7 (24.4, 43.9)          28.0 (23.7, 34.5)            26.7 (21.5, 33.5)          21.1 (20.8, 27.6)            29.7 (19.5, 35.5)               0.44
  Tissue characterization indices                                                                                                                                                                                  
       EGE                                                         5.0 (5.0, 5.0)             5.0 (0.0, 6.0)               4.0 (2.0, 5.0)             4.0 (0.0, 5.0)               6.0 (5.0, 7.0)                  0.34
       LGE (%)                                                     3.0 (2.0, 4.3)             1.8 (1.3, 3.5)               1.6 (1.0, 2.0)             2.5 (1.5, 2.6)               3.0 (1.5, 3.6)                  0.12
       T2 signal ratio                                             2.2 (1.9, 2.7)             2.0 (2.0, 2.0)               1.8 (1.4, 2.4)             1.6 (1.6, 1.7)               2.0 (1.9, 2.1)                  0.15
       Native T1-mapping (msec)                                    1,047.0 (994.0, 1,131.5)   1,058.5 (1,006.0, 1,094.5)   1,012.0 (971.0, 1,024.0)   1,042.0 (1,011.0, 1,079.0)   1,073.0 (1,028.0, 1,125.0)      0.68
       Post-contrast T1-mapping (msec)                             461.5 (440.5, 494.0)       415.5 (358.0, 447.0)         444.0 (392.0, 450.0)       445.0 (418.0, 448.0)         456.0 (439.0, 510.0)            0.12
       ECV (%)                                                     27.5 (26.0, 30.5)          31.0 (28.5, 32.0)            27.0 (25.0, 30.0)          33.0 (26.0, 34.0)            29.0 (28.0, 30.0)               0.25
       T2-mapping (msec)                                           51.0 (48.0, 59.5)          49.5 (48.0, 51.0)            48.0 (47.0, 51.0)          51.0 (50.0, 54.0)            49.0 (49.0, 50.0)               0.30
  Locally-used normal values for tissue characterization indices                                                                                                                                                   
       EGE \>4                                                     6 (30%)                    1 (13%)                      1 (11%)                    0 (0%)                       0 (0%)                          0.31
       LGE \>0%                                                    19 (95%)                   5 (63%)                      8 (89%)                    3 (60%)                      4 (80%)                         0.16
       T2 signal ratio \>1.9                                       13 (65%)                   7 (88%)                      4 (44%)                    1 (20%)                      3 (60%)                         0.14
       Native T1-mapping \>1,050 msec                              8 (40%)                    4 (50%)                      2 (22%)                    2 (40%)                      3 (60%)                         0.67
       Post-contrast T1-mapping \<350 msec                         0 (0%)                     2 (25%)                      1 (11%)                    1 (20%)                      0 (0%)                          0.20
       T2-mapping \>55 msec                                        9 (45%)                    0 (0%)                       0 (0%)                     1 (20%)                      0 (0%)                          0.013^[a](#tfn5-etm-0-0-8693){ref-type="table-fn"}^
       ECV \>28%                                                   7 (35%)                    6 (75%)                      3 (33%)                    3 (60%)                      3 (60%)                         0.28

^a^P≤0.05. ARVC, arrhythmogenic right ventricular cardiomyopathy; DMD/BMD, Duchenne/Becker muscular dystrophy; DCM, dilated cardiomyopathy; LV/RV, left/right ventricular; EDV/ESV, end-diastolic/-systolic volume; EF, ejection fraction; BSA, body surface area; EGE/LGE, early/late gadolinium enhancement; ECV, extracellular volume fraction.

[^1]: *Abbreviations:* PPE, pre-participation sports examination; CMR, cardiovascular magnetic resonance; VRD, ventricular rhythm disturbance; ECG, electrocardiogram; VT, ventricular tachycardia; LGE, late gadolinium enhancement; EGE, early gadolinium enhancement; ECV, extracellular volume fraction; SCD, sudden cardiac death; HCM, hypertrophic cardiomyopathy; PVC, premature ventricular contractions; MOLLI, modified Look-Locker inversion; LV, left ventricle; RV, right ventricle; ESV, end-systolic volume; EDV, end-diastolic volume; EF, ejection fraction; ARVC arrhythmogenic right ventricular cardiomyopathy; DMD Duchenne muscular dystrophy; BMD, Becker muscular dystrophy; MCP, minmax concave penalty; mFDR, marginal false discovery rate; LASSO, least absolute shrinkage and selection operator; BSA, body surface area
